Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol 400 + propylene glycol (Centaur Pharmaceuticals)
- Development stage
- Phase 4
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Healtears Plus is an ophthalmic solution formulated with polyethylene glycol 400 and propylene glycol, developed by Centaur Pharmaceuticals. It is approved for the temporary relief of burning, irritation, and discomfort associated with dry eye syndrome or exposure to environmental factors like wind or sun. The combination acts as a lubricant and humectant, mimicking natural tears to stabilize the tear film, retain moisture, and protect the ocular surface.
- Brand names
- Healtears Plus
- Other names
- polyethylene glycol + propylene glycolpolyethylene glycol and propylene glycol
Beyond the preview
Go deeper on polyethylene glycol 400 + propylene glycol (Centaur Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol 400 + propylene glycol (Centaur Pharmaceuticals).